Biotech Values

[DewDiligence]

TauRx starts phase-3 trials in mild-to-moderate AD:

http://finance.yahoo.com/news/announcing-era-alzheimers-154500640.html

The studies, which have already starting enrolling in the U.S., aim to confirm the disease-modifying effects seen in the Phase 2 studies in mild to moderate patients over an 18-month timeframe. The first study will involve 833 people with mild to moderate Alzheimer's disease over 12 months. The second study will include 500 people with mild Alzheimer's disease over 18 months.

The study drug, LMTX, is a second-generation TAI that targets the Tau tangles and their precursors, dissolving them in order to halt their harmful effects on memory. LMTX also works on the early stage Tau aggregates (called 'oligomers') which are precursors to fully-formed tangles and are thought to be particularly toxic.

LTMX (a/k/a TRx0237) is a successor to TauRx’s Rember (a/k/a TRx-0014, methylene blue). In addition to the two AD trials mentioned above, LTMX is currently in phase-3 for frontotemporal dementia (FTM), an orphan disease. The clinicaltrials.gov listings for the phase-3 trials are:

http://www.clinicaltrials.gov/ct2/show/NCT01689246 (mild-to-moderate AD)
http://www.clinicaltrials.gov/ct2/show/NCT01689233 (mild AD)
http://www.clinicaltrials.gov/ct2/show/NCT01626378 (FTM)

TauRx inked an AD collaboration with Bayer in 2010 (#msg-50894569), but this collaboration is presumably defunct insofar as Bayer is nowhere to be found in the above press release. TauRx is a private company domiciled in Singapore.

p.s. The header of the above PR is rather presumptuous.